# Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-of-the-additional-use-of-ripasudil-a-rho-kinase-inhibitor-in-patients/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Hiroshi Inazaki,Satoshi Kobayashi,Yoko Anzai,Hisayoshi Satoh,Shimpei Sato,Maiko Inoue,Shin Yamane,Kazuaki Kadonosono |
| Citations | 33 |
| DOI | 10.1097/ijg.0000000000000552 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2435409033 |
| PMID | 27661993 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Satoshi Kobayashi](https://scholariq.org/researchers/satoshi-kobayashi/)

## Paper journal

- [Journal of Glaucoma](https://scholariq.org/journals/journal-of-glaucoma/)

## Paper primary topic

- [Glaucoma and retinal disorders](https://scholariq.org/topics/glaucoma-and-retinal-disorders/)

## Paper topics

- [Glaucoma and retinal disorders](https://scholariq.org/topics/glaucoma-and-retinal-disorders/)
- [Corneal surgery and disorders](https://scholariq.org/topics/corneal-surgery-and-disorders/)
- [Retinal Diseases and Treatments](https://scholariq.org/topics/retinal-diseases-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.